Stockwatch: The integrity of the life sciences market
This article was originally published in Scrip
This current earnings season is accompanied by a UK general election, in which the leaders of the three largest parties were last week ridiculed by members of the public during a televised debate for having lost their trust. UK politicians have presented the electorate with expenses scandals, broken promises and much worse, with the result that we no longer believe anything they say. They have lost their integrity.
You may also be interested in...
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.